Recurrent hepatitis C after liver transplantation.

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Hepatitis C virus (HCV) recurrence is a significant complication following liver transplantation, being the leading indication for the procedure in Western Europe and the US.
• Graft reinfection with HCV post-transplantation is nearly universal, with outcomes varying from minimal damage to rapid cirrhosis.

Purpose of the Study:

• To review the natural history, pathogenesis, and current treatment strategies for recurrent hepatitis C after liver transplantation.
• To evaluate the effectiveness of different therapeutic approaches, including antiviral monotherapy and combination therapy, and to discuss future directions in prophylaxis.

Main Methods:

• Literature review of studies on hepatitis C recurrence post-liver transplantation.
• Analysis of data regarding viral and host immune factors influencing disease progression.
• Evaluation of current and emerging treatment modalities for recurrent HCV.

Main Results:

• Recurrent hepatitis C exhibits a variable natural history, with rapid progression to cirrhosis possible.
• HCV recurrence is almost universal after liver transplantation.
• Antiviral monotherapy (interferon or ribavirin) is ineffective for recurrent HCV; preliminary combination therapy results are encouraging.

Conclusions:

• Treatment of recurrent hepatitis C should be considered for patients with significant histological and clinical disease progression.
• Combination therapy shows promise, but further investigation into prophylaxis and its impact on long-term outcomes is warranted.